ChioYokoseMD

Rheumatology • Boston, MA

Physician

Join to view full profile

Dr. Yokose is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yokose's full profile

Already have an account?

Office
55 Fruit Street
Yawkey 2C
Boston, MA 02114

Education & Training

Massachusetts General HospitalFellowship, Rheumatology, 2017 - 2020
NYU Grossman School of MedicineResidency, Internal Medicine, 2014 - 2017
Northwestern University The Feinberg School of MedicineClass of 2014

Certifications & Licensure

MA State Medical License 2017 - 2025
NY State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Publications & Presentations

PubMed

Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization.
Natalie McCormick, Amit D Joshi, Chio Yokose, Bing Yu, Adrienne Tin
Arthritis Care & Research. 2024-12-01
2 citations
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target t...
Natalie McCormick, Chio Yokose, Na Lu, Deborah J Wexler, J Antonio Aviña-Zubieta
BMJ. 2024-10-30
2 citations
Frequently Encountered Artifacts in the Application of Dual-Energy Computed Tomography to Cardiovascular Imaging for Urate Crystals in Gout: A Matched-Control Study.
Chio Yokose, Sterling Ellis Eide, Florian A Huber, F Joseph Simeone, Brian B Ghoshhajra
Arthritis Care & Research. 2024-07-01

Press Mentions

Vaccines Boost Gout Flare Risk, But...August 5th, 2019
Why Does Our Hair Turn Gray?March 30th, 2017
SGLT2 Inhibitors Begin to Show Therapeutic Potential in RheumatologyJanuary 10th, 2024